ImmunityBio
  • Founder’s Vision
  • ANKTIVA®
  • BCG
  • Clinical Trials
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
  • Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Condition
    • Bladder Cancer
    • Glioblastoma
    • HIV
    • Lynch / Colon Cancer
    • Non-Hodgkin Lymphoma
    • Ovarian Cancer
    • Human Papillomavirus
    • Non-Small Cell Lung Cancer
  • Company
    • About Us
    • Investors
    • News and Events
    • Contact
  • Careers
Select Page
A deep learning-based iterative digital pathology annotation tool

A deep learning-based iterative digital pathology annotation tool

Aug 24, 2021 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)

Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)

Jun 4, 2021 | Non-Small Cell Lung Cancer

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

May 20, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.

Apr 16, 2020 | Merkel Cell Carcinoma, Non-Small Cell Lung Cancer

Overcoming hypoxia-induced functional suppression of NK cells

Overcoming hypoxia-induced functional suppression of NK cells

Apr 8, 2020 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

Recent Posts

  • ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
  • ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
  • ImmunityBio to Host Investor Day
  • ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites in the Process of Launching
  • ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap